Rocket Lab USA (NASDAQ: RKLB) has shed 57% from its peak valuation, yet Wall Street analysts remain broadly optimistic, projecting a 49% upside from current trading levels.
The gap between market sentiment and analyst conviction raises a pointed question for investors weighing whether the selloff represents a buying opportunity or a warning sign.
Rocket Lab is one of the largest rocket launch companies in operation, providing launch services to both private sector clients and the U.S. government across an expanding mission portfolio.
Business fundamentals appear strong, with the company recording a landmark 31 launch contracts in the first quarter of 2026, selling more contracts in a single quarter than it did across all of the prior year.
Revenue accelerated sharply in Q1 2026, rising 64% to $200 million, a result that signals growing commercial and governmental demand for the company’s launch capabilities.
The company’s backlog of launch contracts reached $2.2 billion, representing a 108% increase from the same period a year earlier, underscoring the scale of forward demand locking in future revenues.
On profitability, Rocket Lab reported an adjusted EBITDA loss of $11.8 million for the quarter, significantly better than the analyst consensus estimate of a $26 million loss, suggesting operational efficiency is improving faster than expected.
Following the first-quarter results, at least seven analysts raised their price targets on the stock, reflecting renewed confidence in the company’s trajectory despite the broader share price decline.
Further bolstering the bullish case, Rocket Lab announced a $397 million contract with the U.S. government, adding a significant and high-profile revenue commitment to its already substantial backlog.
The central debate for investors now is whether the stock’s steep decline from its peak reflects a mispricing that analysts have correctly identified, or whether broader market caution about the space sector’s profitability timeline is the more reliable signal.
With record contract volumes, accelerating revenue growth, a surging backlog, and a major government deal in hand, the underlying business case for Rocket Lab appears intact even as the share price tells a more complicated story.
